View:
United States securities and exchange commission logo
November 10, 2022
Monica Forbes
Chief Financial Officer
Sesen Bio, Inc.
245 First Street, Suite 1800
Cambridge, MA 02142
Re: Sesen Bio, Inc.
Form 10-K for the
period ended December 31, 2021
Filed February 28,
2022
Form 10-Q for the
period ended September 30, 2022
Filed November 7,
2022
File No. 001-36296
Dear Monica Forbes:
We have limited our review of your filings to the financial
statements and related
disclosures and have the following comments. In some of our comments, we
may ask you to
provide us with information so we may better understand your disclosure.
Please respond to these comments within ten business days by
providing the requested
information or advise us as soon as possible when you will respond. If
you do not believe our
comments apply to your facts and circumstances, please tell us why in
your response.
After reviewing your
response to these comments, we may have additional comments.
Form 10-Q for the period ended September 30, 2022
Notes to Condensed Consolidated Financial Statements
Note 5. Fair Value Measurement and Financial Instruments
Contingent Consideration, page 10
1. Please tell us your
basis for writing off the balance of the estimated earnout payment to
Qilu as of September
30, 2022, citing the authoritative guidance on which you relied
regarding the
extinguishment of the obligation. We note your disclosure that you are in the
process of negotiating
a termination of the Qilu License Agreement and are also seeking
to sell or out-license
Vicineum and all the related obligations related to
Vicineum. However,
until such occurs, and your obligation is legally extinguished, it is
unclear why the
liability was removed from your balance sheet.
Monica Forbes
Sesen Bio, Inc.
November 10, 2022
Page 2
Note 14. Share-Based Compensation, page 19
2. Please tell us what the 3,293,367 issuance of common stock for
share-based compensation
noted in the Condensed Consolidated Statements Of Changes In
Stockholders' Equity for
the three-months ended September 30, 2022 relates to as it is not
clear from your
disclosures.
In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.
You may contact Vanessa Robertson at 202-551-3649 or Sasha Parikh at
202-551-3627
with any questions.
FirstName LastNameMonica Forbes Sincerely,
Comapany NameSesen Bio, Inc.
Division of
Corporation Finance
November 10, 2022 Page 2 Office of Life
Sciences
FirstName LastName